Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964436 | 0.93 | SLC6A9 (0.62) | SLC6A9KCNH2CA12CA1CA7 | |
| SCHEMBL14964132 | 0.91 | SLC6A9 (0.72) | SLC6A9KCNH2CA12CA1CA7 | |
| SCHEMBL7888223 | 0.89 | SLC6A9 (0.60) | SLC6A9KCNH2CA12CA1CA7 | |
| SCHEMBL14957764 | 0.88 | SLC6A9 (0.64) | SLC6A9KCNH2NPY5RTRPV1 | |
| SCHEMBL14957857 | 0.87 | SLC6A9 (0.53) | SLC6A9KCNH2CA12CA1CA7 | |
| SCHEMBL7898347 | 0.84 | SLC6A9 (0.46) | SLC6A9NPY5RTRPV1 | |
| SCHEMBL14957424 | 0.83 | SLC6A9 (0.69) | SLC6A9KCNH2NPY5RTRPV1 | |
| SCHEMBL14962077 | 0.82 | TRPV1 (0.49) | SLC6A9NPY5RTRPV1 | |
| SCHEMBL7896310 | 0.81 | NPY5R (0.47) | SLC6A9CA12CA1CA7CA14 | |
| SCHEMBL3089837 | 0.81 | SLC6A9 (0.81) | SLC6A9KCNH2NPY5RTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846741-B2 | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, NMT1 | SLC6A9 90/4885KCNH2 711/4885CA12 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.